欢迎访问《中国临床药理学与治疗学》杂志官方网站,今天是 分享到:

中国临床药理学与治疗学 ›› 2010, Vol. 15 ›› Issue (2): 185-189.

• 临床药理学 • 上一篇    下一篇

RP-HPLC测定拉米夫定的人体血药浓度及生物等效性研究

孙华1, 赵亚男1, 过怿赟1, 李相鸿1, 杨菁菁1, 冒国光1, 谢海棠2   

  1. 1皖南医学院弋矶山医院临床药理研究所, 2安徽省药物临床评价中心,芜湖 241001,安徽
  • 收稿日期:2009-12-29 修回日期:2010-01-10 出版日期:2010-02-26 发布日期:2020-09-18
  • 通讯作者: 谢海棠,女,博士,副研究员,硕士生导师,研究方向:定量药量学和遗传药理学。Tel: 0553-5738350 E-mail: xiehaitang@sina.com
  • 作者简介:孙华,女,硕士研究生,主管药师,研究方向:临床药理学和定量药量学。Tel: 0553-5739328 E-mail: sunhua9406@163.com

Determination of lamivudine in human plasma by RP-HPLC and its application to bioequivalence research

SUN Hua1, ZHAO Ya-nan1, GUO Yi-yun1, LI Xiang-hong1, YANG Jing-jing1, MAO Guo-guang1, XIE Hai-tang2   

  1. 1 Institute of Clinical Pharmacology, 2 Anhui Provincial Centre for Drug Clinical Evaluation, Yijishan Hospital, Wannan Medical College, Wuhu 241001, Anhui, China
  • Received:2009-12-29 Revised:2010-01-10 Online:2010-02-26 Published:2020-09-18

摘要: 目的:建立人血浆中拉米夫定的HPLC测定法,研究拉米夫定片在健康中国志愿者体内的药动学特征及相对生物利用度。方法:20名健康男性志愿者采用随机分组、双交叉给药方案,分别单剂量口服 0.3 g 的拉米夫定国产制剂与进口制剂,采用RP-HPLC法测定血药浓度,色谱柱为Kromasil C18 柱(250 mm×4.6 mm ID,5 μm),流动相为甲醇: 25 mmol/L 磷酸二氢钾(含体积分数为1%的三乙胺,pH 3.3)(10∶90),流速 1 mL/min,检测波长UV 280 nm。应用DAS 2.1 软件处理数据,计算两组的药代动力学参数及相对生物利用度。结果:拉米夫定在25~7500 μg/L 内线性良好(r=0.9992),血浆中低、中、高3种质量浓度(50、500、5000 μg/L)的相对回收率在 100.09%~103.36%之间,批内RSD≤2.2%,批间RSD≤7.8%。口服 0.3 g 拉米夫定试验制剂(国产)及参比制剂(进口)后的主要药代动学参数如下:Cmax分别为(2835±734)和(2868±726) μg/L;tmax分别为(1.2±0.6)和(1.0±0.8) h;t1/2分别为(2.68±0.32)和(2.58±0.41) h;AUC0-14 h分别为(10994±1839)和(10593±1654) μg·L-1·h;AUC0-∞分别为(11330±1908)和(10884±1734) μg·L-1·h。试验制剂(T)的相对生物利用度为(104.80±15.56)%。结论:本法简便、灵敏、准确、稳定,可用于体内药物分析。国产拉米夫定片与进口片剂具有生物等效性。

关键词: 拉米夫定, 药代动力学, 高效液相色谱法, 生物等效性

Abstract: AIM: To develop a HPLC method for the determination of lamivudine in plasma and study the pharmacokinetics and relative bioavailability of domestic lamivudine tablet in Chinese healthy volunteers. METHODS: A single oral dose (0.3 g) of test tablet (domestic) or reference tablet (imported) was given to each volunteer according to an open randomized crossover study. The concentrations in plasma were determined by RP-HPLC method. The prepared sample was separated on the column of Kromasil C18(250 mm×4.6 mmID,5 μm),with the mobile phase consisting of methanol-25 mmol/L potassium dihydrogen phosphate(containing of 1% triethylamine pH 3.3) (10∶90) at a flow rate of 1 mL/min. The eluted peaks were detected by UV detector at 280 nm. The pharmacokinetic parameters and relative bioavailability were calculated by DAS 2.1. RESULTS: The calibration curve was linear in the range of 25-7500 μg/L(r=0.9992). The relative recoveries of low, medium and high concentration were within 100.09%-103.36%. The intra-batch and inter-batch RSD were less than 2.2% and 7.8%, respectively. The main pharmacokinetic parameters of lamivudine were as follows: Cmax were (2835±734) and (2868±726) μg/L;tmax were (1.15±0.60) and (1.05±0.78) h;t1/2 were (2.68±0.32 ) and (2.58±0.41) h;AUC0-14 h were (10994±1839) and (10593±1654) μg·L-1·h;AUC0-∞ were (11330±1908) and (10884±1734) μg·L-1·h for test and reference preparations, respectively. The relative bioavailability of test tablet was(104.80±15.56)%. CONCLUSION: The assay method is simple, sensitive, accurate and good enough to be used in pharmacokinetic study of lamivudine. The results of statistical analysis show that two preparations in research are bioequivalent.

Key words: Lamivudine, Pharmacokinetics, HPLC, Bioequivalence

中图分类号: